The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Open accessAbstract
BACKGROUND: Of the cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT), acute myeloid leukemia (AML) is most sensitive to natural killer (NK)-cell reactivity. The activating killer-cell immunoglobulin-like receptor (KIR) 2DS1 has ligand specificity for HLA-C2 antigens and activates NK cells in an HLA-dependent manner. Donor-derived NK reactivity controlled by KIR2DS1 and HLA could have beneficial effects in patients with AML who undergo allogeneic HSCT. METHODS: We assessed clinical data, HLA genotyping results, and donor cell lines or genomic DNA for 1277 patients with AML who had received hematopoietic stem-cell transplants from unrelated donors matched for HLA-A, B, C, DR, and DQ or with a single mismatch. We performed donor KIR genotyping and evaluated the clinical effect of donor KIR genotype and donor and recipient HLA genotypes. RESULTS: Patients with AML who received allografts from donors who were positive for KIR2DS1 had a lower rate of relapse than those with allografts from donors who were negative for KIR2DS1 (26.5% vs. 32.5%; hazard ratio, 0.76; 95% confidence interval [CI], 0.61 to 0.96; P=0.02). Of allografts from donors with KIR2DS1, those from donors who were homozygous or heterozygous for HLA-C1 antigens could mediate this antileukemic effect, whereas those from donors who were homozygous for HLA-C2 did not provide any advantage (24.9% with homozygosity or heterozygosity for HLA-C1 vs. 37.3% with homozygosity for HLA-C2; hazard ratio, 0.46; 95% CI, 0.28 to 0.75; P=0.002). Recipients of KIR2DS1-positive allografts mismatched for a single HLA-C locus had a lower relapse rate than recipients of KIR2DS1-negative allografts with a mismatch at the same locus (17.1% vs. 35.6%; hazard ratio, 0.40; 95% CI, 0.20 to 0.78; P=0.007). KIR3DS1, in positive genetic linkage disequilibrium with KIR2DS1, had no effect on leukemia relapse but was associated with decreased mortality (60.1%, vs. 66.9% without KIR3DS1; hazard ratio, 0.83; 95% CI, 0.71 to 0.96; P=0.01). CONCLUSIONS: Activating KIR genes from donors were associated with distinct outcomes of allogeneic HSCT for AML. Donor KIR2DS1 appeared to provide protection against relapse in an HLA-C-dependent manner, and donor KIR3DS1 was associated with reduced mortality. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Lee, S. J., Klein, J., Haagenson, M., Baxter-Lowe, L. A., Confer, D. L., Eapen, M., Fernandez-Vina, M., Flomenberg, N., Horowitz, M., Hurley, C. K., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097386 · Cited by 1,255
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038687 · Cited by 616
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Self-citationGiebel, S. (2003) · Blood · doi:10.1182/blood-2003-01-0091 · Cited by 549
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors
Stewart, C. A., Laugier-Anfossi, F., Vély, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagné, F., Ferracci, G., Arosa, F. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503594102 · Cited by 406
Hsu, K. C., Liu, X.-R., Selvakumar, A., Mickelson, E., O’Reilly, R. J., & Dupont, B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5118 · Cited by 381
Self-citationPende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Montagna, D., Romeo, E., Cognet, C., Martinetti, M., Maccario, R., et al. (2009) · Blood · doi:10.1182/blood-2008-06-164103 · Cited by 378
Human natural killer cell receptors and co‐receptors
Biassoni, R., Cantoni, C., Pende, D., Sivori, S., Parolini, S., Vitale, M., Bottino, C., & Moretta, A. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1810117.x · Cited by 324
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors
Fauriat, C., Ivarsson, M. A., Ljunggren, H.-G., Malmberg, K.-J., & Michaëlsson, J. (2010) · Blood · doi:10.1182/blood-2009-09-245746 · Cited by 305
Limits of HLA mismatching in unrelated hematopoietic cell transplantation
Petersdorf, E. W., Anasetti, C., Martin, P. J., Gooley, T., Radich, J., Malkki, M., Woolfrey, A., Smith, A., Mickelson, E., & Hansen, J. A. (2004) · Blood · doi:10.1182/blood-2004-04-1674 · Cited by 263
Self-citationWillemze, R., Rodrigues, C. A., Labopin, M., Sanz, G., Michel, G., Socié, G., Rio, B., Sirvent, A., Renaud, M., Madero, L., et al. (2009) · Leukemia · doi:10.1038/leu.2008.365 · Cited by 245
Farag, S. S., Bacigalupo, A., Eapen, M., Hurley, C., Dupont, B., Caligiuri, M. A., Boudreau, C., Nelson, G., Oudshoorn, M., van Rood, J., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.05.007 · Cited by 243
Self-citationGlobal diversity and evidence for coevolution of KIR and HLA
Single, R. M., Martin, M. P., Gao, X., Meyer, D., Yeager, M., Kidd, J. R., Kidd, K. K., & Carrington, M. (2007) · Nature Genetics · doi:10.1038/ng2077 · Cited by 229
Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., Moretta, L., & Moretta, A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271203 · Cited by 213
Hsu, K. C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.-D., Bornhäuser, M., Christiansen, F., Gratwohl, A., Morishima, Y., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.04.008 · Cited by 212
Self-citationWoolfrey, A., Klein, J. P., Haagenson, M., Spellman, S., Petersdorf, E., Oudshoorn, M., Gajewski, J., Hale, G. A., Horan, J., Battiwalla, M., et al. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.09.012 · Cited by 210
Self-citationKIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro
Chewning, J. H., Gudme, C. N., Hsu, K. C., Selvakumar, A., & Dupont, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.854 · Cited by 186
Self-citationCook, M. A., Milligan, D. W., Fegan, C. D., Darbyshire, P. J., Mahendra, P., Craddock, C. F., Moss, P. A. H., & Briggs, D. C. (2004) · Blood · doi:10.1182/blood-2003-02-0438 · Cited by 177
Continuous engagement of a self-specific activation receptor induces NK cell tolerance
Tripathy, S. K., Keyel, P. A., Yang, L., Pingel, J. T., Cheng, T. P., Schneeberger, A., & Yokoyama, W. M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072446 · Cited by 176
Function of NKG2D in natural killer cell–mediated rejection of mouse bone marrow grafts
Ogasawara, K., Benjamin, J., Takaki, R., Phillips, J. H., & Lanier, L. L. (2005) · Nature Immunology · doi:10.1038/ni1236 · Cited by 169
Tolerance of NK cells encountering their viral ligand during development
Sun, J. C.-Y., & Lanier, L. L. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072448 · Cited by 125
Sivori, S., Carlomagno, S., Falco, M., Romeo, E., Moretta, L., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-10-316125 · Cited by 119
Gagne, K., Busson, M., Bignon, J., Balère, M.-L., Loiseau, P., Dormoy, A., Dubois, V., Perrier, P., Jollet, I., Bois, M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.015 · Cited by 47
Cited by
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Sorror, M. L., Storb, R. F., Sandmaier, B. M., Maziarz, R. T., Pulsipher, M. A., Maris, M. B., Bhatia, S., Ostronoff, F., Deeg, H. J., Syrjala, K. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8157 · Cited by 423
Metadata
- Authors
- Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., & Hsu, K. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-08-30
- Volume
- 367
- Issue
- 9
- Pages
- 805-816
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2007509667
- Cited by
- 429
- References
- 27
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.